Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Continuous Precision Medicine
AddedFeb 18, 2024
UpdatedJun 18, 2026
Continuous Precision Medicine

Continuous Precision Medicine

Seed

CPM: Leading the fight against opioid abuse with personalized medication management tools.

HQ
Raleigh, NC, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Continuous Precision Medicine (CPM) was founded with the core mission of combating opioid addiction through personalized medication management. The company's vision is to provide innovative and effective solutions to one of the most costly and emotionally damaging healthcare issues. CPM offers tools designed to manage medication in a controlled and personalized manner, focusing on preventative care to achieve definitive results. Their market focus is primarily on healthcare providers and patients dealing with opioid dependency.

Notable affiliated people and investors include experts in healthcare technology and addiction treatment, though specific names are not provided. Key achievements of CPM include the development of advanced tools that have shown promise in reducing opioid misuse and improving patient outcomes. The overall impact of CPM has been significant in the realm of opioid addiction, providing both patients and healthcare providers with essential resources to manage and prevent abuse effectively.

Continuous Precision Medicine - Quick Facts

When was Continuous Precision Medicine founded?

Continuous Precision Medicine was founded in 2016.

Where is Continuous Precision Medicine's headquarters located?

Continuous Precision Medicine's headquarters is located in Raleigh, NC, US.

When was Continuous Precision Medicine's last funding round?

Continuous Precision Medicine's most recent funding round was for $769.9k (USD) in September 2016.

How much has Continuous Precision Medicine raised to-date?

As of Sep 28, 2016, Continuous Precision Medicine has raised a total of $769.9k (USD).

How many employees does Continuous Precision Medicine have?

Continuous Precision Medicine has 5 employees as of Feb 5, 2024.

Continuous Precision Medicine - Classification

Ownership
  • Venture Capital
Technology
  • Analytics
Geographic Exposure
  • United States
Revenue
  • Recurring
  • SaaS
Main Product
  • Medication Management
Tags
  • Healthcare
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 7 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software